SCHEMBL2952964

SCHEMBL2952964

CN(C)CCNc1ccnc(N(Cc2ccccn2)Cc2ccccn2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.57
HRH3 Q9Y5N1 1/20 0.53
DNM2 P50570 2/20 0.46
APP P05067 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
LIN28A Q9H9Z2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP2D6 P10635 1/20 0.40
SLC40A1 Q9NP59 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
MKNK1 Q9BUB5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945980 0.80 HRH3 (0.53) CYP2C19HRH3DNM2SMN1; SMN2MAPT
SCHEMBL2943994 0.76 HRH3 (0.56) CYP2C19HRH3DNM2SMN1; SMN2MAPT
SCHEMBL4440939 0.74 CYP2C19 (1.00) CYP2C19HRH3DNM2CYP1A2KDM4E
SCHEMBL29943771 0.74 CYP2C19 (1.00) CYP2C19HRH3DNM2CYP1A2KDM4E
SCHEMBL1091654 0.71 HRH3 (0.60) CYP2C19HRH3DNM2HRH4MKNK1
SCHEMBL11456527 0.71 CYP2C19 (0.56) CYP2C19HRH3DNM2APP
SCHEMBL20024598 0.71 CYP2C19 (0.51) CYP2C19HRH3SMN1; SMN2MAPTLIN28A
SCHEMBL1319889 0.70 HRH3 (0.67) CYP2C19HRH3DNM2HRH4MKNK1
SCHEMBL16840340 0.70 HRH3 (1.00) CYP2C19HRH3DNM2HRH4
SCHEMBL11162995 0.69 CYP2C19 (0.75) CYP2C19HRH3DNM2APPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CYP2C19 1062/4885HRH3 94/4885DNM2 4429/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CYP2C19 1062/4885HRH3 94/4885DNM2 4429/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CYP2C19 1062/4885HRH3 94/4885DNM2 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.